Dual targeting of conserved cell cycle and transcription programs in advanced colorectal cancer by fadraciclib
Our results using patient-derived models suggest that fadraciclib is a promising therapy for advanced CRC by inhibiting CDKs 2 and 9, which affects critical pathways in cell cycle regulation and transcription.
Authors
- Jason A. Somarelli (ORCID: https://orcid.org/0000-0003-1510-9343)
- David S. Hsu (ORCID: https://orcid.org/0000-0002-8149-7180)
- Shannon J. McCall (ORCID: https://orcid.org/0000-0003-3957-061X)
- David Blake (ORCID: https://orcid.org/0000-0002-8367-3256)
- John B. Mantyh (ORCID: https://orcid.org/0009-0006-7431-7985)
- Mohammad Zokaasadi (ORCID: https://orcid.org/0000-0001-8957-0541)
- Gabrielle Rupprecht (ORCID: https://orcid.org/0000-0003-3711-862X)
- Wylie K. Watlington (ORCID: https://orcid.org/0009-0004-5335-6518)
- Divya L. Dayanidhi (ORCID: https://orcid.org/0009-0000-3610-167X)
Institutions
- Duke University (US)
- Duke Medical Center (US)
- Cyclacel Pharmaceuticals (United Kingdom) (GB)
Publication Details
- Journal
- Evolution Medicine and Public Health
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/emph/eoaf021
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Cancer Institute